Illumina, Sophia Genetics to Comarket NGS Solutions for Clinical Dx | GenomeWeb

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has signed a co-marketing agreement with Illumina that allows the companies jointly market their respective products and solutions to hospitals and clinical laboratories.

Initially, the companies will market their combined products to customers in the EMEA region, Sophia said. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.